Ansbert Gadicke

Dr. Gadicke is co-founder and Managing Director of MPM Capital and its venture capital activities as well as an investment committee member of its oncology-only crossover investment strategy (both public and private equities). Dr. Gadicke led the company-building efforts of several of MPM’s most successful investments including BioMarin Pharmaceuticals, Idenix Pharmaceuticals (acquired by Merck & Co.), Mitobridge (acquired by Astellas), Pharmasset (acquired by Gilead Sciences), and Radius Health – companies that are helping thousands of patients live longer and vastly improved lives. Sovaldi, developed by Pharmasset, was the first cure for Hepatitis C and experienced the most successful product launch in the pharmaceutical industry. Prior to founding MPM, Dr. Gadicke was at The Boston Consulting Group. Dr. Gadicke, active in guiding MPM portfolio companies, also serves as Chairman of the Board at Cullinan Oncology and is a member of the Board of ElevateBio and iTeos Therapeutics. He is also a member of the Board of Fellows of Harvard Medical School and the Research Advisory Council of the Massachusetts General Hospital. He received an MD from J.W. Goethe University in Frankfurt and held research positions at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology and the Biochemistry Department at Harvard University. While at the German Cancer Research Center, he focused on HPV16 and 18 in Professor Harald zur Hausen’s group (Nobel Laureate in Physiology or Medicine, 2008). Ansbert has published in leading scientific journals such as Nature and Cell.